Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials
ObjectivesThis paper presents a systematic review aimed at assessing the therapeutic potential of sulforaphane (SFN) in the treatment of diverse cancer types.MethodsFollowing Cochrane guidelines for systematic reviews, we conducted an exhaustive search of electronic databases up to May 12, 2023, enc...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1251895/full |
| _version_ | 1797464797296459776 |
|---|---|
| author | Dana ElKhalifa Nour Al-Ziftawi Ahmed Awaisu Feras Alali Ashraf Khalil |
| author_facet | Dana ElKhalifa Nour Al-Ziftawi Ahmed Awaisu Feras Alali Ashraf Khalil |
| author_sort | Dana ElKhalifa |
| collection | DOAJ |
| description | ObjectivesThis paper presents a systematic review aimed at assessing the therapeutic potential of sulforaphane (SFN) in the treatment of diverse cancer types.MethodsFollowing Cochrane guidelines for systematic reviews, we conducted an exhaustive search of electronic databases up to May 12, 2023, encompassing PubMed, Cochrane, Embase, Web of Science, Google Scholar, Natural Medicines, ProQuest, ClinicalTrials.gov, and ICTRP. Studies were included if they were human-based RCTs involving cancer patients where SFN was the primary experimental treatment. The Cochrane Risk of Bias tool for RCTs (RoB2) was used for quality assessment.ResultsEight studies investigating the efficacy and safety of SFN in prostate cancer (PCa), breast cancer, pancreatic cancer, and melanoma were identified and included in the review. The dosing regimens were variable and inconsistent across the studies. SFN treatment led to statistically significant alterations in several vital genes and histological biomarkers across the studies. However, it did not impact some other key genes. Although not statistically significant, SFN improved overall survival in pancreatic cancer patients. The results on prostate-specific antigen (PSA) were inconsistent in PCa. None of the studies reported significant differences between SFN and comparative controls in terms of adverse events.ConclusionSFN has emerged as a promising and safe therapeutic agent for diverse cancer types. Nevertheless, the high levels of methodological and clinical heterogeneity across the included studies precluded the possibility of conducting meta-analyses. Further robust clinical investigations to conclusively ascertain the chemotherapeutic potential of SFN in the management of various cancer forms are needed.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022323788, identifier CRD42022323788. |
| first_indexed | 2024-03-09T18:12:16Z |
| format | Article |
| id | doaj.art-e2ad9536b4d0412ca1462f18bd6e553f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-09T18:12:16Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-e2ad9536b4d0412ca1462f18bd6e553f2023-11-24T09:03:01ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-11-011310.3389/fonc.2023.12518951251895Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trialsDana ElKhalifa0Nour Al-Ziftawi1Ahmed Awaisu2Feras Alali3Ashraf Khalil4Department of Pharmacy, Aspetar Orthopedic and Sports Medicine Hospital, Doha, QatarDepartment of Pharmacy, Aman Hospital, Doha, QatarCollege of Pharmacy, QU Health, Qatar University, Doha, QatarCollege of Pharmacy, QU Health, Qatar University, Doha, QatarCollege of Pharmacy, QU Health, Qatar University, Doha, QatarObjectivesThis paper presents a systematic review aimed at assessing the therapeutic potential of sulforaphane (SFN) in the treatment of diverse cancer types.MethodsFollowing Cochrane guidelines for systematic reviews, we conducted an exhaustive search of electronic databases up to May 12, 2023, encompassing PubMed, Cochrane, Embase, Web of Science, Google Scholar, Natural Medicines, ProQuest, ClinicalTrials.gov, and ICTRP. Studies were included if they were human-based RCTs involving cancer patients where SFN was the primary experimental treatment. The Cochrane Risk of Bias tool for RCTs (RoB2) was used for quality assessment.ResultsEight studies investigating the efficacy and safety of SFN in prostate cancer (PCa), breast cancer, pancreatic cancer, and melanoma were identified and included in the review. The dosing regimens were variable and inconsistent across the studies. SFN treatment led to statistically significant alterations in several vital genes and histological biomarkers across the studies. However, it did not impact some other key genes. Although not statistically significant, SFN improved overall survival in pancreatic cancer patients. The results on prostate-specific antigen (PSA) were inconsistent in PCa. None of the studies reported significant differences between SFN and comparative controls in terms of adverse events.ConclusionSFN has emerged as a promising and safe therapeutic agent for diverse cancer types. Nevertheless, the high levels of methodological and clinical heterogeneity across the included studies precluded the possibility of conducting meta-analyses. Further robust clinical investigations to conclusively ascertain the chemotherapeutic potential of SFN in the management of various cancer forms are needed.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022323788, identifier CRD42022323788.https://www.frontiersin.org/articles/10.3389/fonc.2023.1251895/fullcancersulforaphaneisothiocyanatesglucoraphaninbroccolicruciferous vegetables |
| spellingShingle | Dana ElKhalifa Nour Al-Ziftawi Ahmed Awaisu Feras Alali Ashraf Khalil Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials Frontiers in Oncology cancer sulforaphane isothiocyanates glucoraphanin broccoli cruciferous vegetables |
| title | Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials |
| title_full | Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials |
| title_fullStr | Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials |
| title_full_unstemmed | Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials |
| title_short | Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials |
| title_sort | efficacy and tolerability of sulforaphane in the therapeutic management of cancers a systematic review of randomized controlled trials |
| topic | cancer sulforaphane isothiocyanates glucoraphanin broccoli cruciferous vegetables |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1251895/full |
| work_keys_str_mv | AT danaelkhalifa efficacyandtolerabilityofsulforaphaneinthetherapeuticmanagementofcancersasystematicreviewofrandomizedcontrolledtrials AT nouralziftawi efficacyandtolerabilityofsulforaphaneinthetherapeuticmanagementofcancersasystematicreviewofrandomizedcontrolledtrials AT ahmedawaisu efficacyandtolerabilityofsulforaphaneinthetherapeuticmanagementofcancersasystematicreviewofrandomizedcontrolledtrials AT ferasalali efficacyandtolerabilityofsulforaphaneinthetherapeuticmanagementofcancersasystematicreviewofrandomizedcontrolledtrials AT ashrafkhalil efficacyandtolerabilityofsulforaphaneinthetherapeuticmanagementofcancersasystematicreviewofrandomizedcontrolledtrials |